SRP 001
Alternative Names: SRP 3D (diethylamide); SRP-001; SRP-3D-(DA)Latest Information Update: 04 Jan 2024
At a glance
- Originator South Rampart Pharma
- Class Acetanilides; Aminophenols; Analgesics; Antipyretics; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists; Cyclo-oxygenase 2 inhibitors; Cytochrome P-450 enzyme system inhibitors; Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 02 Jan 2024 Adverse events and pharmacokinetics data from a phase I trial in Pain released by South Rampart Pharma
- 02 Jan 2024 South Rampart Pharma completes a phase I trial in Pain (In volunteers) in USA (PO) (NCT05484414)
- 01 Nov 2023 South Rampart Pharma has patent protection for compositions and methods for ameliorating pain including SRP 001 and other compounds in USA, EU, China, Hong Kong, Japan, India, Australia, South Korea, Canada, Brazil, Russia, and Mexico